Regencell Bioscience Holdings Limited cash flow statement RGC
In fiscal 2026, which ended Jun 30, 2026, Regencell Bioscience Holdings Limited used $7.7 million of cash from operations, down 147.2% from the year before.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
|---|---|---|---|---|---|---|
| Operating | ||||||
| Depreciation and amortization |
0
+4.1%
|
0
-74.6%
|
0
+4.3%
|
0
+95.2%
|
0
+467.5%
|
0
|
| Stock-based compensation |
3
+1217.6%
|
0
-45.5%
|
0
-51.3%
|
1
-66.5%
|
3
|
—
|
| Operating cash flow |
-8
-147.2%
|
-3
+22.2%
|
-4
+19.4%
|
-5
+5.8%
|
-5
-586.4%
|
-1
|
| Investing | ||||||
| Capital expenditures |
—
|
0
+2740.2%
|
0
-80.4%
|
0
-96.5%
|
1
+562.7%
|
—
|
| Investing cash flow |
3
-6.8%
|
3
-48.8%
|
5
+8789.1%
|
0
+100.5%
|
-11
-9049.0%
|
—
|
| Financing | ||||||
| Financing cash flow |
17
+16467.8%
|
—
|
0
-24.2%
|
0
-99.4%
|
22
+4995.1%
|
0
|
| Change in cash | ||||||
| Effect of exchange rate |
0
+116.5%
|
-0
-315.6%
|
0
+164.0%
|
-0
|
—
|
—
|
| Net change in cash |
12
+2271.7%
|
-1
-138.8%
|
1
+128.8%
|
-5
|
—
|
—
|
| Free cash flow |
—
|
-3
+18.5%
|
-4
+19.7%
|
-5
+17.5%
|
-6
-583.3%
|
—
|
| Per share | ||||||
| Free cash flow per share |
—
|
-0.01
+18.5%
|
-0.01
+19.7%
|
-0.01
+97.9%
|
-0.47
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- RGC (Nasdaq)
- Incorporated in
- Cayman Islands
- Headquarters
- Hong Kong
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1829667
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.